Gbola Amusa
Stock Analyst at Chardan Capital
(1.25)
# 2,569
Out of 4,480 analysts
36
Total ratings
40.91%
Success rate
2.9%
Average return
Main Sectors:
19 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADVM Adverum Biotechnologies | Downgrades: Neutral | $200 → $50 | $6.84 | +630.99% | 2 | Apr 29, 2021 | |
| TSHA Taysha Gene Therapies | Maintains: Buy | n/a | $2.16 | - | 3 | Apr 13, 2021 | |
| FBRX Forte Biosciences | Maintains: Buy | n/a | $0.52 | - | 4 | Mar 17, 2021 | |
| SLDB Solid Biosciences | Maintains: Buy | n/a | $5.96 | - | 3 | Mar 16, 2021 | |
| PASG Passage Bio | Maintains: Buy | n/a | $1.00 | - | 1 | Mar 8, 2021 | |
| MCRB Seres Therapeutics | Upgrades: Buy | n/a | $0.70 | - | 2 | Mar 5, 2021 | |
| QURE uniQure | Maintains: Buy | n/a | $4.01 | - | 2 | Mar 2, 2021 | |
| SYBX Synlogic | Maintains: Buy | n/a | $1.43 | - | 1 | Jan 13, 2021 | |
| IMVT Immunovant | Maintains: Buy | n/a | $26.52 | - | 3 | Aug 25, 2020 | |
| KRYS Krystal Biotech | Maintains: Buy | n/a | $177.61 | - | 1 | Aug 19, 2020 | |
| IOVA Iovance Biotherapeutics | Maintains: Buy | n/a | $7.73 | - | 2 | Aug 7, 2020 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | n/a | $53.12 | - | 1 | Jul 28, 2020 | |
| MRNA Moderna | Maintains: Buy | n/a | $117.07 | - | 2 | Jul 15, 2020 | |
| FOLD Amicus Therapeutics | Downgrades: Neutral | n/a | $9.85 | - | 1 | Aug 17, 2018 | |
| RGNX REGENXBIO | Maintains: Buy | n/a | $10.75 | - | 4 | Jul 16, 2018 | |
| ESPR Esperion Therapeutics | Maintains: Neutral | n/a | $2.34 | - | 1 | Mar 27, 2018 | |
| AXON Axon Enterprise | Upgrades: Neutral | n/a | $293.18 | - | 1 | Jan 10, 2018 | |
| SAGE Sage Therapeutics | Upgrades: Buy | n/a | $10.82 | - | 1 | Nov 10, 2017 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Neutral | n/a | $1,044.66 | - | 1 | Dec 12, 2016 |
Adverum Biotechnologies
Apr 29, 2021
Downgrades: Neutral
Price Target: $200 → $50
Current: $6.84
Upside: +630.99%
Taysha Gene Therapies
Apr 13, 2021
Maintains: Buy
Price Target: n/a
Current: $2.16
Upside: -
Forte Biosciences
Mar 17, 2021
Maintains: Buy
Price Target: n/a
Current: $0.52
Upside: -
Solid Biosciences
Mar 16, 2021
Maintains: Buy
Price Target: n/a
Current: $5.96
Upside: -
Passage Bio
Mar 8, 2021
Maintains: Buy
Price Target: n/a
Current: $1.00
Upside: -
Seres Therapeutics
Mar 5, 2021
Upgrades: Buy
Price Target: n/a
Current: $0.70
Upside: -
uniQure
Mar 2, 2021
Maintains: Buy
Price Target: n/a
Current: $4.01
Upside: -
Synlogic
Jan 13, 2021
Maintains: Buy
Price Target: n/a
Current: $1.43
Upside: -
Immunovant
Aug 25, 2020
Maintains: Buy
Price Target: n/a
Current: $26.52
Upside: -
Krystal Biotech
Aug 19, 2020
Maintains: Buy
Price Target: n/a
Current: $177.61
Upside: -
Iovance Biotherapeutics
Aug 7, 2020
Maintains: Buy
Price Target: n/a
Current: $7.73
Upside: -
CRISPR Therapeutics AG
Jul 28, 2020
Maintains: Buy
Price Target: n/a
Current: $53.12
Upside: -
Moderna
Jul 15, 2020
Maintains: Buy
Price Target: n/a
Current: $117.07
Upside: -
Amicus Therapeutics
Aug 17, 2018
Downgrades: Neutral
Price Target: n/a
Current: $9.85
Upside: -
REGENXBIO
Jul 16, 2018
Maintains: Buy
Price Target: n/a
Current: $10.75
Upside: -
Esperion Therapeutics
Mar 27, 2018
Maintains: Neutral
Price Target: n/a
Current: $2.34
Upside: -
Axon Enterprise
Jan 10, 2018
Upgrades: Neutral
Price Target: n/a
Current: $293.18
Upside: -
Sage Therapeutics
Nov 10, 2017
Upgrades: Buy
Price Target: n/a
Current: $10.82
Upside: -
Regeneron Pharmaceuticals
Dec 12, 2016
Upgrades: Neutral
Price Target: n/a
Current: $1,044.66
Upside: -